2023
Real-World Treatment Patterns Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents
Zeidan A, Costantino H, Modi K, Salimi T, Washington T, Epstein R. Real-World Treatment Patterns Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents. Blood 2023, 142: 548. DOI: 10.1182/blood-2023-188638.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeOral DECHMA therapyMedian ageTreatment patternsCCI scoreAML diagnosisMyelodysplastic syndromeSC cohortReal-world treatment patternsReal-world clinical practiceEnd of enrollmentMean CCI scorePre-index periodPrescription claims dataDiscontinuation of treatmentHalf of patientsDays of administrationStandard of careTreatment of MDSEnd of studyLongitudinal persistenceOral decitabineIndex dateTreatment cohorts
2020
Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with Myelodysplastic Syndromes
Abel G, Klepin H, Magnavita E, Jaung T, Shallis R, Bahl N, Dellinger-Johnston R, Winer E, Zeidan A. Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with Myelodysplastic Syndromes. Blood 2020, 136: 25-26. DOI: 10.1182/blood-2020-139919.Peer-Reviewed Original ResearchECOG performance statusQuality of lifePerformance statusRBC transfusionMyelodysplastic syndromeExact testRed blood cell transfusionPatients' QOLDana-Farber Cancer InstituteTwo-sided Fisher's exact testMore RBC transfusionsPre-transfusion HbSetting of anemiaBlood cell transfusionHalf of patientsPost-transfusion increaseFisher's exact testCell transfusionPatient characteristicsUnstable anginaMedian HbMean ageTransfusion decisionsHb thresholdQoL assessment